{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:43:44Z","timestamp":1789155824950,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13555-023-01008-9","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T17:01:57Z","timestamp":1694451717000},"page":"2443-2460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase\u00a03 Trials"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03956355","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03983980","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04053387","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3022-5169","authenticated-orcid":false,"given":"Seemal R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Golant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Lewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Butners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"issue":"8","key":"1008_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CE. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940\u20136.","journal-title":"JAMA Dermatol"},{"issue":"19","key":"1008_CR2","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1001\/jama.2022.5270","volume":"327","author":"K Walter","year":"2022","unstructured":"Walter K. Psoriasis. JAMA. 2022;327(19):1936\u20131936.","journal-title":"JAMA"},{"issue":"2 Suppl 2","key":"1008_CR3","first-page":"S36","volume":"35","author":"GL Stein","year":"2016","unstructured":"Stein GL. Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg. 2016;35(2 Suppl 2):S36\u201344.","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"1008_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et al. Joint AAD\u2013NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1008_CR5","doi-asserted-by":"publisher","first-page":"100116","DOI":"10.1016\/j.xjidi.2022.100116","volume":"2","author":"D Tian","year":"2022","unstructured":"Tian D, Lai Y. The relapse of psoriasis: what\u2019s the veil of mystery? JID Innov. 2022;2:100116.","journal-title":"JID Innov"},{"key":"1008_CR6","unstructured":"Dermavant Sciences. VTAMA (tapinarof) cream, 1%: FDA label. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215272s000lbl.pdf. Accessed Jan 2023."},{"issue":"24","key":"1008_CR7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","volume":"385","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, et al. Phase\u00a03 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"1008_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","volume":"87","author":"B Strober","year":"2022","unstructured":"Strober B, Gold LS, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1008_CR9","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1468-3083.2011.04332.x","volume":"26","author":"R Bissonnette","year":"2012","unstructured":"Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1008_CR10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","volume":"80","author":"K Robbins","year":"2019","unstructured":"Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase\u00a02, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermaol. 2019;80(3):714\u201321.","journal-title":"J Am Acad Dermaol"},{"issue":"3","key":"1008_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaad.2020.04.181","volume":"84","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Bhatia N, Tallman AM, Rubenstein DS. A phase\u00a02b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes. J Am Acad Dermatol. 2021;84(3):624\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1008_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40257-021-00641-4","volume":"23","author":"JE Jett","year":"2022","unstructured":"Jett JE, McLaughlin M, Lee MS, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83\u201391.","journal-title":"Am J Clin Dermatol"},{"key":"1008_CR13","unstructured":"Lebwohl M, Stein Gold L, Strober B, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: efficacy and safety in two pivotal phase\u00a03 trials. In: Presentation at the European Academy of Dermatology and Venereology (virtual), October 28\u2013November 1, 2020."},{"key":"1008_CR14","doi-asserted-by":"crossref","unstructured":"Stein Gold L, Blauvelt A, Armstrong A, et al. Tapinarof cream 1% once daily for plaque psoriasis: secondary efficacy outcomes from two pivotal phase\u00a03 trials. In: Poster at the American Academy of Dermatology (virtual), April 23\u201325, 2021.","DOI":"10.1016\/j.jaad.2021.06.300"},{"key":"1008_CR15","doi-asserted-by":"crossref","unstructured":"Bissonnette R, Strober B, Lebwohl M, et al. Tapinarof cream 1% once daily for plaque psoriasis: patient-reported outcomes from two pivotal phase\u00a03 trials. In: Poster at the American Academy of Dermatology VMX (virtual), April 23\u201325, 2021.","DOI":"10.1016\/j.jaad.2021.06.310"},{"key":"1008_CR16","doi-asserted-by":"crossref","unstructured":"Kircik L, Zirwas M, Kwatra SG, et al. Rapid improvements in itch with tapinarof cream 1% once daily in two phase\u00a03 trials in adults with mild to severe plaque psoriasis. In: Poster at the Winter Clinical Dermatology Conference, January 13\u201318, 2023.","DOI":"10.25251\/skin.7.supp.126"},{"key":"1008_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.061","author":"J Bagel","year":"2023","unstructured":"Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: patient reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.061.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1008_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"1008_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","volume":"23","author":"D Pathirana","year":"2009","unstructured":"Pathirana D, Ormerod A, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1008_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase\u00a02, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89\u201398.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1008_CR21","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Investig Dermatol. 2017;137(10):2110\u20139.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"1008_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.36849\/JDD.6627","volume":"21","author":"J Jett","year":"2022","unstructured":"Jett J, McLaughlin M, Wilson T, et al. Dermal safety of tapinarof cream 1%: results from 4 phase 1 trials. J Drugs Dermatol. 2022;21(10):1084\u201390.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"1008_CR23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/jdv.16246","volume":"34","author":"A Al-Janabi","year":"2020","unstructured":"Al-Janabi A, Foulkes A, Mason K, Smith C, Griffiths C, Warren R. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1440\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1008_CR24","doi-asserted-by":"publisher","DOI":"10.2196\/36102","volume":"11","author":"S Wongvibulsin","year":"2022","unstructured":"Wongvibulsin S, Feterik K. Recommendations for better adoption of medical photography as a clinical tool. Interact J Med Res. 2022;11(2):e36102.","journal-title":"Interact J Med Res"},{"issue":"1","key":"1008_CR25","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.jaad.2021.03.006","volume":"85","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Gold LS, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy. J Am Acad Dermatol. 2021;85(1):e39\u201340.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01008-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T15:33:58Z","timestamp":1703172838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01008-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01008-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Seemal R. Desai has served as a consultant and investigator for Dermavant Sciences, Inc.; he also serves in multiple other leadership and industry roles unrelated to tapinarof cream 1%. Linda Stein Gold has served as a consultant, and\/or has received payment for the development of educational presentations, and\/or has received grants from Amgen, Arcutis, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB Biopharma. Michael C. Cameron has served as a consultant, advisor, or speaker for AbbVie, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, EPI Health, Evelo Biosciences, Incyte, Journey Medical, LEO Pharma, Regeneron, and Ortho Pharmaceuticals. Alexandra Golant has received consulting or speaking fees from AbbVie, Amgen, Arcutis, Dermavant Sciences, Inc., Eli Lilly, Evelo Biosciences, Incyte, Janssen, LEO Pharma, Regeneron, and Sanofi. G. Michael Lewitt has served as a consultant, speaker, investigator, or advisory board member and\/or has received grants from AbbVie, Amgen, Inc., Bristol Myers Squibb, Dermavant Sciences, Inc., DermTech, Eli Lilly, Galderma, LEO Pharma, Janssen, Novan, Inc., Pfizer, Ortho Dermatologics, and UCB Biopharma. Matthew J. Bruno has served as a consultant and\/or received payment for promotional presentations from AbbVie, Almirall, Bristol Myers Squibb, Dermavant Sciences, Inc., EPI Health, Journey Medical Corporation, Mayne Pharma, Medimetriks Pharmaceuticals, Pfizer, Regeneron\/Sanofi-Genzyme, and Sun Pharmaceuticals. George Martin has served as a speaker and\/or consultant and\/or has been involved in scientific advisory boards for AbbVie, Almirall, Alumis, Bristol Myers Squibb, Celgene, Dermavant Sciences, Inc., DUSA\/Sun, Eli Lilly, Evelo, Galderma, Horizon, Incyte, Janssen, LEO Pharma, Nobelpharma, Ortho\/Bausch Health, Organogenesis, Pfizer, Trevi, and UCB Biopharma. Philip M. Brown, David S. Rubenstein, Victoria Butners, and Anna M. Tallman are employees of Dermavant Sciences, Inc., with stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trials were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Approval was obtained from the local ethics committee or institutional review board for each trial center. All the patients provided written informed consent and photographic release.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}